Allergic asthma is a chronic inflammatory disease characterized by airway inflammation, changes in structural activity, and bronchial hyperactivity. Scientists have tried to mimic such features of human allergic asthma in murine models as the prevalence of asthma in westernized countries has nearly doubled over the last 20 years to an estimated 180,000 asthma-related deaths per year (WHO, 2018). To date there is no cure for asthma; treatment efforts including inhalers, diet intervention and steroidal injection are designed for symptom relief (Roland et al., 2018). Other initiatives include electronic health recording (EHR) allowing patients to co-manage disease in between office visits. Such interventions and therapies are temporary, aiming to minimize severity of symptoms and number of office visits but they do not always alter underlying pathological mechanisms. Thus, suitable efficacy models are needed. The Ovalbumin (OVA) and House Dust Mite (HDM)-induced models are widely-used models to explore underlying pathogenesis of asthma and MD Biosciences is proud to offer both models as resources for testing new therapeutics as well as provide additional ex vivo assessment services to better understand therapeutic method of action.
